Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparisons Of Inflammatory Biomarkers And Cardiovascular Risk Scores Before And After Conversion To Full Dose Myfortic Using Two Hour Neoral Monitoring.

Next Previous
Trial Profile

Comparisons Of Inflammatory Biomarkers And Cardiovascular Risk Scores Before And After Conversion To Full Dose Myfortic Using Two Hour Neoral Monitoring.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary) ; Mycophenolate sodium (Primary) ; Mycophenolate mofetil; Prednisone
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms COBACAM

Most Recent Events

  • 05 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Oct 2015.
  • 05 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Oct 2015.
  • 05 Jan 2017 Planned initiation date changed from 1 Jan 2016 to 1 Feb 2014.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top